Replimune Group (REPL)
(Real Time Quote from BATS)
$6.16 USD
-0.17 (-2.69%)
Updated Apr 25, 2024 03:52 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
REPL 6.16 -0.17(-2.69%)
Will REPL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for REPL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REPL
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
REPL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
Is a Surprise Coming for Replimune (REPL) This Earnings Season?
Other News for REPL
The Melanoma Research Foundation to host the New England Miles for Melanoma 5K
Commit To Buy Replimune Group At $5, Earn 10.2% Annualized Using Options
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)